BioSpace News Archive

Athersys, Inc. announced that it intends to offer and sell shares of its common stock and warrants to purchase common stock, subject to market and other conditions, in a public offering.

Amgen (NASDAQ:AMGN) today announced that clinical and real-world data across its broad portfolio of established treatments and pipeline assets will be presented at the annual American College of Rheumatology Convergence (ACR), taking place in Philadelphia on Nov. 10-14, 2022.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it will report its financial results for the quarter ended September 30, 2022 on Thursday, November 10th.

Know Labs, Inc. will present at the second annual Bernstein CGM Disruptors Conference www.bernsteinresearch.com on Friday, Nov. 18, 2022.

Meissa Vaccines (“Meissa”), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced interim clinical data of MV-012-968, Meissa’s intranasal live attenuated RSV vaccine candidate, from a Phase 1c study in RSV-naïve (seronegative) infants and young children.

Maxwell Biosciences announced the appointment of Kate McKinley and Douglas S. Boothe to its Board of Directors.

Nucleai, a leader in AI-powered spatial biology, today announced the expansion of its spatial biology platform to include a new generation of multiplex immunofluorescence (mIF) analysis that uses deep learning to establish new levels of accuracy, speed, and generalizability, further unlocking the power of mIF data for drug discovery and development.

Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it has extended its line of Haloperidol Tablets, USP and is now offering unit dose packaging in 1 mg, 5 mg, and 10 mg strengths.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, reported its second quarter 2022 financial results and operational highlights, restatement of first quarter 2022 financial results and the provision of third quarter 2022 estimates.

Philogen S.p.A., a clinical-stage biotechnology company focused on the development of innovative medicines based on tumor targeting antibodies and small molecule ligands, announces the publication of a study in the peer-reviewed journal “Chem” describing the design, development and the in vivo characterization of novel OncoFAP ligands.